Seattle Genetics Highlights ADCETRIS A Data in Relapsed Hodgkin Lymphoma and Other CD30-Positive Malignancies from Multiple Presentations at ASH Annual Meeting -Investigator Analysis Shows Median Overall Survival for ADCETRIS-Treated Relapsed HL Patients after ASCT Was 91 Months Compared with 28 Months among Non-ADCETRIS Patients- -ADCETRIS ... (more)
http://eon.businesswire.com/news/eon/20121210005428/en/Seattle-Genetics-Highlights-ADCETRIS%C2%AE-Brentuximab-Vedotin-Data
http://eon.businesswire.com/news/eon/20121210005428/en/Seattle-Genetics-Highlights-ADCETRIS%C2%AE-Brentuximab-Vedotin-Data
No comments:
Post a Comment